The use of an IVA protocol with a PTEN inhibitor in human cryopreserved ovarian cortex from cancer patients increased the pool of viable activated primordial follicles without inducing deleterious effects, as the obtained results indicate. The gene discussed is PTEN; the disease is cancer.